Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Endo Health Solutions Inc Reaffirms FY 2012 EPS Guidance; Issues FY 2013 Guidance Below Analysts' Estimates
Endo Health Solutions Inc announced that for fiscal 2012, it expects adjusted diluted earnings per share (EPS) in the range of $5.00 to $5.10 and GAAP diluted earnings per share in the range of $0.87-$0.97. For fiscal 2013, it expects total revenue between $2.80-$2.95 billion, adjusted diluted earnings per share between $4.40-$4.70 According to I/B/E/S Estimates, analysts on an average are expecting the Company to report EPS of $5.00 for fiscal 2012; revenue of $3.05 billion and EPS of $5.08 for fiscal 2013.
Latest Key Developments in Pharmaceuticals
- Yantai Dongcheng Biochemicals Co Ltd to Acquire Equity Shares in China-based Company
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Share this
- Link this
- Digg this
Follow Reuters